In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio
Keywords: Prostate cancer; PARP inhibitors; AZD-2281; Gut toxicity; EF5; Gamma H2AX; Clonogenic assay; Growth delay;